nach oben

International Journal of Hematology

Erschienen in:

01.05.2015 | Progress in Hematology

Prophylactic and therapeutic treatment of graft-versus-host disease in Japan

verfasst von: Makoto Murata

Erschienen in: International Journal of Hematology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Allogeneic hematopoietic stem cell transplantation in Japan is very different from that in Western countries in terms of the homogeneous genetic background, the preference for bone marrow to peripheral blood stem cells, use of a single unit in cord blood transplantation, and frequent use of non-myeloablative preconditioning due to a large number of elderly patients. Therefore, conclusions obtained from well-designed prospective and/or comparative studies of treatment of graft-versus-host disease (GVHD) performed in the United States or Europe may not fit Japanese transplant patients. This article reviews the studies of prophylactic and therapeutic treatment of acute and chronic GVHD that have been conducted in Japan. A randomized study demonstrated a lower incidence of acute GVHD in tacrolimus-based prophylaxis than in cyclosporine A-based prophylaxis. Retrospective and non-randomized prospective studies suggest that cyclosporine A-based and tacrolimus-based GVHD prophylaxis regimens are well researched and nearly optimized for Japanese patients, including infusion methods and target blood concentration. However, most other studies were performed in a single institute including a small number of patients, resulting in biased conclusions. There is no conclusive report on steroid-refractory acute and chronic GVHD. This review provides a baseline for starting prospective studies to create new evidence for GVHD treatment from Japan.

Oh H, Loberiza FR Jr, Zhang MJ, Ringdén O, Akiyama H, Asai T, et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood. 2005;105:1408–16.PubMedCrossRef

Morishima Y, Kawase T, Malkki M, Morishima S, Spellman S, Kashiwase K, et al. Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2013;19:1197–203.CrossRef

Ozawa S, Nakaseko C, Nishimura M, Maruta A, Cho R, Ohwada C, et al. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. Br J Haematol. 2007;137:142–51.PubMedCrossRef

Kanda J, Nakasone H, Atsuta Y, Toubai T, Yokoyama H, Fukuda T, et al. Risk factors and organ involvement of chronic GVHD in Japan. Bone Marrow Transpl. 2014;49:228–35.CrossRef

Kuwatsuka Y, Atsuta Y, Horowitz MM, Inagaki J, Kanda J, Kato K, et al. Graft-versus-host disease and survival after cord blood transplantation for acute leukemia: a comparison of Japanese versus White populations. Biol Blood Marrow Transpl. 2014;20:662–7.CrossRef

Maeda Y. Pathogenesis of graft-versus-host disease: innate immunity amplifying acute alloimmune responses. Int J Hematol. 2013;98:293–9.PubMedCrossRef

Kanda J. Effect of HLA mismatch on acute graft-versus-host disease. Int J Hematol. 2013;98:300–8.PubMedCrossRef

Takami A. Role of non-HLA gene polymorphisms in graft-versus-host disease. Int J Hematol. 2013;98:309–18.PubMedCrossRef

Paczesny S, Raiker N, Brooks S, Mumaw C. Graft-versus-host disease biomarkers: omics and personalized medicine. Int J Hematol. 2013;98:275–92.PubMedCentralPubMedCrossRef

10.

Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729–35.PubMedCrossRef

11.

Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P, et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood. 1986;68:119–25.PubMed

12.

Morishima Y, Morishita Y, Tanimoto M, Ohno R, Saito H, Horibe K, et al. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group. Blood. 1989;74:2252–6.PubMed

13.

Morishima Y, Kodera Y, Hirabayashi N, Tanimoto M, Matsuyama T, Horibe K, et al. Low incidence of acute GVHD in patients transplanted with marrow from HLA-A, B, DR-compatible unrelated donors among Japanese. Bone Marrow Transpl. 1995;15:235–9.

14.

Kanda Y, Izutsu K, Hirai H, Sakamaki H, Iseki T, Kodera Y, et al. Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate. Leukemia. 2004;18:1013–9.PubMedCrossRef

15.

Gondo H, Harada M, Taniguchi S, Akashi K, Hayashi S, Teshima T, et al. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease. Bone Marrow Transpl. 1993;12:437–41.

16.

Ogawa N, Kanda Y, Matsubara M, Asano Y, Nakagawa M, Sakata-Yanagimoto M, et al. Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion. Bone Marrow Transpl. 2004;33:549–52.CrossRef

17.

Umeda K, Adachi S, Tanaka S, Ogawa A, Hatakeyama N, Kudo K, et al. Comparison of continuous and twice-daily infusions of cyclosporine A for graft-versus-host-disease prophylaxis in pediatric hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2014. doi:10.1002/pbc.25243 (Epub ahead of print, PubMed PMID: 25307105).

18.

Kanda Y, Hyo R, Yamashita T, Fujimaki K, Oshima K, Onoda M, et al. Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor. Am J Hematol. 2006;81:838–44.PubMedCrossRef

19.

Oshima K, Kanda Y, Nakasone H, Arai S, Nishimoto N, Sato H, et al. Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level. Am J Hematol. 2008;83:226–32.PubMedCrossRef

20.

Machishima T, Kako S, Wada H, Yamasaki R, Ishihara Y, Kawamura K, et al. The safety and efficacy of acute graft-versus-host disease prophylaxis with a higher target blood concentration of cyclosporine around 500 ng/mL. Clin Transpl. 2013;27:749–56.

21.

Kohno A, Morishita Y, Iida H, Sakamaki H, Yokozawa T, Kitaori K, et al. Low-dose cyclosporin A with short-term methotrexate for graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation from human leukocyte antigen-identical siblings: a prospective phase II study in Japanese patients. Int J Hematol. 2006;84:83–9.PubMedCrossRef

22.

Izumi N, Furukawa T, Sato N, Okazuka K, Tsukada N, Abe T, et al. Risk factors for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: retrospective analysis of 73 patients who received cyclosporin A. Bone Marrow Transpl. 2007;40:875–80.CrossRef

23.

Furukawa T, Kurasaki-Ida T, Masuko M, Tsukada N, Okazuka K, Sato N, et al. Pharmacokinetic and pharmacodynamic analysis of cyclosporine A (CsA) to find the best single time point for the monitoring and adjusting of CsA dose using twice-daily 3-h intravenous infusions in allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2010;92:144–51.PubMedCrossRef

24.

Nawa Y, Hara M, Tanimoto K, Nakase K, Kozuka T, Maeda Y. Single-dose daily infusion of cyclosporine for prevention of graft-versus-host disease after allogeneic bone marrow transplantation from HLA allele-matched, unrelated donors. Int J Hematol. 2006;83:159–63.PubMedCrossRef

25.

Nagamura F, Takahashi T, Takeuchi M, Iseki T, Ooi J, Tomonari A, et al. Effect of cyclophosphamide on serum cyclosporine levels at the conditioning of hematopoietic stem cell transplantation. Bone Marrow Transpl. 2003;32:1051–8.CrossRef

26.

Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92:2303–14.PubMed

27.

Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96:2062–8.PubMed

28.

Hiraoka A, Ohashi Y, Okamoto S, Moriyama Y, Nagao T, Kodera Y, et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transpl. 2001;28:181–5.CrossRef

29.

Nishida T, Murayama T, Hirai H, Okamoto S, Sao H, Hara M, et al. Phase II study of tacrolimus and methotrexate for prophylaxis of acute graft-versus-host disease after HLA-A, B, and DRB1 genotypically mismatched unrelated bone marrow transplantation among Japanese patients. Int J Hematol. 2009;89:98–105.PubMedCrossRef

30.

Yanada M, Emi N, Naoe T, Sakamaki H, Takahashi S, Hirabayashi N, et al. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. Bone Marrow Transpl. 2004;34:331–7.CrossRef

31.

Nakasone H, Fukuda T, Kanda J, Mori T, Yano S, Kobayashi T, et al. Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation. Bone Marrow Transpl. 2015;50:559–65CrossRef

32.

Watanabe N, Matsumoto K, Muramatsu H, Horibe K, Matsuyama T, Kojima S, et al. Relationship between tacrolimus blood concentrations and clinical outcome during the first 4 weeks after SCT in children. Bone Marrow Transpl. 2010;45:1161–6.CrossRef

33.

Mori T, Kato J, Shimizu T, Aisa Y, Nakazato T, Yamane A, et al. Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors. Biol Blood Marrow Transpl. 2012;18:229–34.CrossRef

34.

Yano S, Mori S, Saito T, Yokoyama H, Machishima T, Shimada T, et al. Pharmacokinetics for once-daily modified release formulation of tacrolimus hydrate in unrelated hematopoietic stem cell transplantation. Ann Hematol. 2015;94:491–6.PubMedCrossRef

35.

Ogawa H, Soma T, Hosen N, Tatekawa T, Tsuboi A, Oji Y, et al. Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation. Transplantation. 2002;74:236–43.PubMedCrossRef

36.

Yagasaki H, Kojima S, Yabe H, Kato K, Kigasawa H, Sakamaki H, et al. Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis. Biol Blood Marrow Transpl. 2009;15:1603–8.CrossRef

37.

Nasu R, Nannya Y, Shinohara A, Ichikawa M, Kurokawa M. Favorable outcomes of tacrolimus compared with cyclosporine A for GVHD prophylaxis in HSCT for standard-risk hematological diseases. Ann Hematol. 2014;93:1215–23.PubMedCrossRef

38.

Nishida T, Hamaguchi M, Hirabayashi N, Haneda M, Terakura S, Atsuta Y, et al. Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transpl. 2004;33:1143–50.CrossRef

39.

Inamoto Y, Ito M, Suzuki R, Nishida T, Iida H, Kohno A, et al. Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy. Bone Marrow Transpl. 2009;44:43–9.CrossRef

40.

Fujino M, Kim Y, Ito M. Intestinal thrombotic microangiopathy induced by FK506 in rats. Bone Marrow Transpl. 2007;39:367–72.CrossRef

41.

Kanekiyo T, Hara J, Matsuda-Hashii Y, Fujisaki H, Tokimasa S, Sawada A, et al. Tacrolimus-related encephalopathy following allogeneic stem cell transplantation in children. Int J Hematol. 2005;81:264–8.PubMedCrossRef

42.

Onizuka M, Kunii N, Toyosaki M, Machida S, Ohgiya D, Ogawa Y, et al. Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients. Bone Marrow Transpl. 2011;46:1113–7.CrossRef

43.

Koga Y, Nagatoshi Y, Kawano Y, Okamura J. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan. Bone Marrow Transpl. 2003;32:171–6.CrossRef

44.

Watanabe N, Matsumoto K, Yoshimi A, Horibe K, Matsuyama T, Kojima S, et al. Outcome of bone marrow transplantation from HLA-identical sibling donor in children with hematological malignancies using methotrexate alone as prophylaxis for graft-versus-host disease. Int J Hematol. 2008;88:575–82.PubMedCrossRef

45.

Sugita J, Matsushita T, Kashiwazaki H, Kosugi M, Takahashi S, Wakasa K, et al. Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD. Bone Marrow Transpl. 2012;47:258–64.CrossRef

46.

Kodama Y, Fukano R, Noguchi M, Okamura J, Inagaki J. Folinic acid after MTX as prophylaxis for GVHD in pediatric bone marrow transplantation. Int J Hematol. 2015;101:92–8.PubMedCrossRef

47.

Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transpl. 2004;34:621–5.CrossRef

48.

Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Fernandez H, Ayala E, et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transpl. 2010;16:937–47.CrossRef

49.

Mizumoto C, Kanda J, Ichinohe T, Ishikawa T, Matsui M, Kadowaki N, et al. Mycophenolate mofetil combined with tacrolimus and minidose methotrexate after unrelated donor bone marrow transplantation with reduced-intensity conditioning. Int J Hematol. 2009;89:538–45.PubMedCrossRef

50.

Nishikawa S, Okamura A, Yamamori M, Minagawa K, Kawamori Y, Kawano Y, et al. Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host disease. Transpl Proc. 2009;41:3873–6.CrossRef

51.

Wakahashi K, Yamamori M, Minagawa K, Ishii S, Nishikawa S, Shimoyama M, et al. Pharmacokinetics-based optimal dose prediction of donor source-dependent response to mycophenolate mofetil in unrelated hematopoietic cell transplantation. Int J Hematol. 2011;94:193–202.PubMedCrossRef

52.

Iida M, Fukuda T, Ikegame K, Yoshihara S, Ogawa H, Taniguchi S, et al. Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan. Int J Hematol. 2011;93:523–31.PubMedCrossRef

53.

Iida M, Fukuda T, Uchida N, Murata M, Aotsuka N, Minagawa K, et al. Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan. Clin Transpl. 2014;28:980–9.CrossRef

54.

Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98:2942–7.PubMedCrossRef

55.

Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transpl. 2006;12:560–5.CrossRef

56.

Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855–64.PubMedCrossRef

57.

Socié G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood. 2011;117:6375–82.PubMedCrossRef

58.

Theurich S, Fischmann H, Shimabukuro-Vornhagen A, Chemnitz JM, Holtick U, Scheid C, et al. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database Syst Rev. 2012;9:CD009159.

59.

Azuma E, Kojima S, Kato K, Matsuyama T, Yamada Y, Kondo N, et al. Conditioning with cyclophosphamide/antithymocyte globulin for allogeneic bone marrow transplantation from HLA-matched siblings in children with severe aplastic anemia. Bone Marrow Transpl. 1997;19:1085–7.CrossRef

60.

Kojima S, Inaba J, Yoshimi A, Takahashi Y, Watanabe N, Kudo K, et al. Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation. Br J Haematol. 2001;114:706–11.PubMedCrossRef

61.

Kojima S, Matsuyama T, Kato S, Kigasawa H, Kobayashi R, Kikuta A, et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood. 2002;100:799–803.PubMedCrossRef

62.

Terasako K, Sato K, Sato M, Kimura S, Nakasone H, Okuda S, et al. The effect of different ATG preparations on immune recovery after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia. Hematology. 2010;15:165–9.PubMedCrossRef

63.

Kanda Y, Oshima K, Kako S, Fukuda T, Uchida N, Miyamura K, et al. In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation. Am J Hematol. 2013;88:294–300.PubMedCrossRef

64.

Nakai K, Mineishi S, Kami M, Saito T, Hori A, Kojima R, et al. Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution. Transplantation. 2003;75:2135–43.PubMedCrossRef

65.

Teshima T, Matsuo K, Matsue K, Kawano F, Taniguchi S, Hara M, et al. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors. Br J Haematol. 2005;130:575–87.PubMedCrossRef

66.

Tanosaki R, Uike N, Utsunomiya A, Saburi Y, Masuda M, Tomonaga M, et al. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome. Biol Blood Marrow Transpl. 2008;14:702–8.CrossRef

67.

Fuji S, Ueno N, Hiramoto N, Asakura Y, Yakushijin K, Kamiyama Y, et al. Reduced-intensity conditioning regimen with low-dose ATG-F for unrelated bone marrow transplant is associated with lower non-relapse mortality than a regimen with low-dose TBI: a single-center retrospective analysis of 103 cases. Int J Hematol. 2013;98:608–14.PubMedCrossRef

68.

Hatanaka K, Fuji S, Ikegame K, Kato R, Wake A, Hidaka M, et al. Low incidences of acute and chronic graft-versus-host disease after unrelated bone marrow transplantation with low-dose anti-T lymphocyte globulin. Int J Hematol. 2012;96:773–80.PubMedCrossRef

69.

Sao H, Kitaori K, Kasai M, Shimokawa T, Kato C, Yamanishi H, et al. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I–II trial. Int J Hematol. 1999;69:27–35.PubMed

70.

Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351:2276–85.PubMedCrossRef

71.

Brunstein CG, Barker JN, Weisdorf DJ, DeFor TE, Miller JS, Blazar BR, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood. 2007;110:3064–70.PubMedCentralPubMedCrossRef

72.

Kurtzberg J, Prasad VK, Carter SL, Wagner JE, Baxter-Lowe LA, Wall D, et al. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood. 2008;112:4318–27.PubMedCentralPubMedCrossRef

73.

Cutler C, Stevenson K, Kim HT, Brown J, McDonough S, Herrera M, et al. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transpl. 2011;46:659–67.CrossRef

74.

Ruggeri A, Sanz G, Bittencourt H, Sanz J, Rambaldi A, Volt F, et al. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. Leukemia. 2014;28:779–86.PubMedCrossRef

75.

Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood. 2004;104:3813–20.PubMedCrossRef

76.

Ooi J, Iseki T, Takahashi S, Tomonari A, Takasugi K, Shimohakamada Y, et al. Unrelated cord blood transplantation for adult patients with de novo acute myeloid leukemia. Blood. 2004;103:489–91.PubMedCrossRef

77.

Takahashi S, Ooi J, Tomonari A, Konuma T, Tsukada N, Oiwa-Monna M, et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood. 2007;109:1322–30.PubMedCrossRef

78.

Ooi J, Takahashi S, Tomonari A, Tsukada N, Konuma T, Kato S, et al. Unrelated cord blood transplantation after myeloablative conditioning in adults with acute myelogenous leukemia. Biol Blood Marrow Transpl. 2008;14:1341–7.CrossRef

79.

Konuma T, Takahashi S, Ooi J, Tomonari A, Tsukada N, Kato S, et al. Myeloablative unrelated cord blood transplantation for acute leukemia patients between 50 and 55 years of age: single institutional retrospective comparison with patients younger than 50 years of age. Ann Hematol. 2009;88:581–8.PubMedCrossRef

80.

Sato A, Ooi J, Takahashi S, Tsukada N, Kato S, Kawakita T, et al. Unrelated cord blood transplantation after myeloablative conditioning in adults with advanced myelodysplastic syndromes. Bone Marrow Transpl. 2011;46:257–61.CrossRef

81.

Miyakoshi S, Yuji K, Kami M, Kusumi E, Kishi Y, Kobayashi K, et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. Clin Cancer Res. 2004;10:3586–92.PubMedCrossRef

82.

Kishi Y, Kami M, Miyakoshi S, Kanda Y, Murashige N, Teshima T, et al. Early immune reaction after reduced-intensity cord-blood transplantation for adult patients. Transplantation. 2005;80:34–40.PubMedCrossRef

83.

Miyakoshi S, Kami M, Tanimoto T, Yamaguchi T, Narimatsu H, Kusumi E, et al. Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases. Transplantation. 2007;84:316–22.PubMedCrossRef

84.

Uchida N, Wake A, Takagi S, Yamamoto H, Kato D, Matsuhashi Y, et al. Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases. Biol Blood Marrow Transpl. 2008;14:583–90.CrossRef

85.

Uchida N, Wake A, Nakano N, Ishiwata K, Takagi S, Tsuji M, et al. Mycophenolate and tacrolimus for graft-versus-host disease prophylaxis for elderly after cord blood transplantation: a matched pair comparison with tacrolimus alone. Transplantation. 2011;92:366–71.PubMedCrossRef

86.

Arai Y, Kondo T, Kitano T, Hishizawa M, Yamashita K, Kadowaki N, et al. Monitoring mycophenolate mofetil is necessary for the effective prophylaxis of acute GVHD after cord blood transplantation. Bone Marrow Transpl. 2015;50:312–4.CrossRef

87.

Mori T, Aisa Y, Nakazato T, Yamazaki R, Shimizu T, Mihara A, et al. Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies. Transpl Proc. 2007;39:1615–9.CrossRef

88.

Yamada MF, Miyamura K, Fujiwara T, Kohata K, Okitsu Y, Ohguchi H, et al. Myeloablative cord blood transplantation for adults with hematological malignancies using tacrolimus and short-term methotrexate for graft-versus-host disease prophylaxis: single-institution analysis. Transpl Proc. 2008;40:3637–42.CrossRef

89.

Narimatsu H, Terakura S, Matsuo K, Oba T, Uchida T, Iida H, et al. Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults. Bone Marrow Transpl. 2007;39:31–9.CrossRef

90.

Kato K, Yoshimi A, Ito E, Oki K, Hara J, Nagatoshi Y, et al. Cord blood transplantation from unrelated donors for children with acute lymphoblastic leukemia in Japan: the impact of methotrexate on clinical outcomes. Biol Blood Marrow Transpl. 2011;17:1814–21.CrossRef

91.

Kanda J, Atsuta Y, Wake A, Ichinohe T, Takanashi M, Morishima Y, et al. Impact of the direction of HLA mismatch on transplantation outcomes in single unrelated cord blood transplantation. Biol Blood Marrow Transpl. 2013;19:247–54.CrossRef

92.

Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23:3447–54.PubMedCrossRef

93.

Huang XJ, Zhu HH, Chang YJ, Xu LP, Liu DH, Zhang XH, et al. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood. 2012;119:5584–90.PubMedCrossRef

94.

Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai HL, Bolaños-Meade J, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transpl. 2010;16:482–9.CrossRef

95.

Yabe H, Yabe M, Hattori K, Hinohara T, Morimoto T, Nakamura Y, et al. Successful engraftment of allogeneic CD34-enriched marrow cell transplantation from HLA-mismatched parental donors. Bone Marrow Transpl. 1996;17:985–91.

96.

Kawano Y, Takaue Y, Watanabe A, Takeda O, Arai K, Itoh E, et al. Partially mismatched pediatric transplants with allogeneic CD34(+) blood cells from a related donor. Blood. 1998;92:3123–30.PubMed

97.

Matsuda Y, Hara J, Osugi Y, Fujisaki H, Takai K, Ohta H, et al. Allogeneic peripheral stem cell transplantation using positively selected CD34+ cells from HLA-mismatched donors. Bone Marrow Transpl. 1998;21:355–60.CrossRef

98.

Shimazaki C, Ochiai N, Uchida R, Okano A, Fuchida S, Ashihara E, et al. Non-T-cell-depleted HLA haploidentical stem cell transplantation in advanced hematologic malignancies based on the feto-maternal michrochimerism. Blood. 2003;101:3334–6.PubMedCrossRef

99.

Obama K, Utsunomiya A, Takatsuka Y, Takemoto Y. Reduced-intensity non-T-cell depleted HLA-haploidentical stem cell transplantation for older patients based on the concept of feto-maternal tolerance. Bone Marrow Transpl. 2004;34:897–9.CrossRef

100.

Yabe H, Inoue H, Matsumoto M, Hamanoue S, Hiroi A, Koike T, et al. Unmanipulated HLA-haploidentical bone marrow transplantation for the treatment of fatal, nonmalignant diseases in children and adolescents. Int J Hematol. 2004;80:78–82.PubMedCrossRef

101.

Ichinohe T, Uchiyama T, Shimazaki C, Matsuo K, Tamaki S, Hino M, et al. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism. Blood. 2004;104:3821–8.PubMedCrossRef

102.

Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T, et al. Unmanipulated HLA 2–3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transpl. 2006;12:1073–84.CrossRef

103.

Ogawa H, Ikegame K, Kaida K, Yoshihara S, Fujioka T, Taniguchi Y, et al. Unmanipulated HLA 2–3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Exp Hematol. 2008;36:1–8.PubMedCrossRef

104.

Ikegame K, Kaida K, Yoshihara S, Fujiwara M, Taniguchi K, Kato R, et al. Feasibility of unmanipulated haploidentical stem cell transplantation using standard GVHD prophylaxis for HLA-homozygous patients. Int J Hematol. 2012;96:101–8.PubMedCrossRef

105.

Kaida K, Ikegame K, Ikemoto J, Murata R, Irie R, Yoshihara S, et al. Soluble interleukin-2 receptor level on day 7 as a predictor of graft-versus-host disease after HLA-haploidentical stem cell transplantation using reduced-intensity conditioning. Int J Hematol. 2014;99:463–70.PubMedCrossRef

106.

Yoshihara T, Okada K, Kobayashi M, Kikuta A, Kato K, Adachi N, et al. Outcome of non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents. Int J Hematol. 2007;85:246–55.PubMedCrossRef

107.

Kurokawa T, Ishiyama K, Ozaki J, Yamashita Y, Iwaki N, Saito C, et al. Haploidentical hematopoietic stem cell transplantation to adults with hematologic malignancies: analysis of 66 cases at a single Japanese center. Int J Hematol. 2010;91:661–9.PubMedCrossRef

108.

Mochizuki K, Kikuta A, Ito M, Sano H, Akaihata M, Kobayashi S, et al. Feasibility of tacrolimus, methotrexate, and prednisolone as a graft-versus-host disease prophylaxis in non-T-cell-depleted haploidentical hematopoietic stem cell transplantation for children. Clin Transpl. 2011;25:892–7.CrossRef

109.

Kanda Y, Oshima K, Asano-Mori Y, Kandabashi K, Nakagawa M, Sakata-Yanagimoto M, et al. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation. 2005;79:1351–7.PubMedCrossRef

110.

Sawada A, Shimizu M, Isaka K, Higuchi K, Mayumi A, Yoshimoto Y, et al. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for advanced pediatric malignancies. Pediatr Hematol Oncol. 2014;31:754–64.PubMedCrossRef

111.

Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011;117:6963–70.PubMedCentralPubMedCrossRef

112.

Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2012;18:1150–63.CrossRef

113.

Van Lint MT, Uderzo C, Locasciulli A, Majolino I, Scimé R, Locatelli F, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood. 1998;92:2288–93.PubMed

114.

Mielcarek M, Storer BE, Boeckh M, Carpenter PA, McDonald GB, Deeg HJ, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood. 2009;113:2888–94.PubMedCentralPubMedCrossRef

115.

Cahn JY, Bordigoni P, Tiberghien P, Milpied N, Brion A, Widjenes J, et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation. 1995;60:939–42.PubMedCrossRef

116.

Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy PL Jr, et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood. 2004;104:1559–64.PubMedCrossRef

117.

Cragg L, Blazar BR, Defor T, Kolatker N, Miller W, Kersey J, et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transpl. 2000;6:441–7.CrossRef

118.

Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood. 2008;111:2470–5.PubMedCentralPubMedCrossRef

119.

Couriel DR, Saliba R, de Lima M, Giralt S, Andersson B, Khouri I, et al. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transpl. 2009;15:1555–62.CrossRef

120.

Alousi AM, Weisdorf DJ, Logan BR, Bolaños-Meade J, Carter S, Difronzo N, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2009;114:511–7.PubMedCentralPubMedCrossRef

121.

Hockenbery DM, Cruickshank S, Rodell TC, Gooley T, Schuening F, Rowley S, et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood. 2007;109:4557–63.PubMedCrossRef

122.

Murata M, Nakasone H, Kanda J, Nakane T, Furukawa T, Fukuda T, et al. Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: an analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl. 2013;19:1183–9.CrossRef

123.

Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990;76:1464–72.PubMed

124.

MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood. 2010;115:5412–7.PubMedCrossRef

125.

Takashima S, Eto T, Shiratsuchi M, Hidaka M, Mori Y, Kato K, et al. The use of oral beclomethasone dipropionate in the treatment of gastrointestinal graft-versus-host disease: the experience of the Fukuoka blood and marrow transplantation (BMT) group. Intern Med. 2014;53:1315–20.PubMedCrossRef

126.

Kanamaru A, Takemoto Y, Kakishita E, Dohy H, Kodera Y, Moriyama Y, et al. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. Bone Marrow Transpl. 1995;15:885–9.

127.

Ohashi K, Tanaka Y, Mori S, Okuyama Y, Hiruma K, Akiyama H, et al. Low-dose antithymocyte globulin for treatment of steroid-pulse-resistant acute graft-versus-host disease. Int J Hematol. 2003;77:99–102.PubMedCrossRef

128.

Nishimoto M, Nakamae H, Koh H, Nakamae M, Hirose A, Hayashi Y, et al. Response-guided therapy for steroid-refractory acute GVHD starting with very-low-dose antithymocyte globulin. Exp Hematol. 2015;43:177–9PubMedCrossRef

129.

Takami A, Mochizuki K, Okumura H, Ito S, Suga Y, Yamazaki H, et al. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. Int J Hematol. 2006;83:80–5.PubMedCrossRef

130.

Onishi C, Ohashi K, Sawada T, Nakano M, Kobayashi T, Yamashita T, et al. A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease. Int J Hematol. 2010;91:464–70.PubMedCrossRef

131.

Inagaki J, Nagatoshi Y, Hatano M, Isomura N, Sakiyama M, Okamura J. Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children. Bone Marrow Transpl. 2008;41:571–7.CrossRef

132.

Inagaki J, Fukano R, Kodama Y, Nishimura M, Shimokawa M, Okamura J. Safety and efficacy of low-dose methotrexate for pediatric patients with steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation. Ann Hematol. 2014;93:645–51.PubMedCrossRef

133.

Muroi K, Miyamura K, Ohashi K, Murata M, Eto T, Kobayashi N, et al. Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study. Int J Hematol. 2013;98:206–13.PubMedCrossRef

134.

Wakatabe K, Miyamura K, Ozawa Y, Okada M, Yamashita T, Murata M, et al. Efficacy of mesenchymal stem cells for the treatment of steroid-refractory aGVHD. In: 56th ASH annual meeting and exposition, Dec 6–9, 2014, San Francisco, CA, (abstract#3913).

135.

Inoue M, Okamura T, Sawada A, Kawa K. Colostrum and severe gut GVHD. Bone Marrow Transpl. 1998;22:402–3.CrossRef

136.

Wada H, Mori A, Okada M, Takatsuka H, Tamura A, Seto Y, et al. Treatment of intestinal graft-versus-host disease using betamethasone enemas. Transplantation. 2001;72:1451–3.PubMedCrossRef

137.

Yamane T, Yamamura R, Aoyama Y, Nakamae H, Hasegawa T, Sakamoto C, et al. Infliximab for the treatment of severe steroid refractory acute graft-versus-host disease in three patients after allogeneic hematopoietic transplantation. Leuk Lymphoma. 2003;44:2095–7.PubMedCrossRef

138.

Iyama S, Murase K, Sato T, Hashimoto A, Tatekoshi A, Horiguchi H, et al. Narrowband ultraviolet B phototherapy ameliorates acute graft-versus-host disease by a mechanism involving in vivo expansion of CD4+ CD25+ Foxp3+ regulatory T cells. Int J Hematol. 2014;99:471–6.PubMedCrossRef

139.

Nakane T, Fukuda T, Kanda J, Taniguchi S, Eto T, Ohashi K, et al. Age influences post-graft-versus-host disease non-relapse mortality in adults with acute graft-versus-host disease of varying severity following allogeneic hematopoietic cell transplant. Leuk Lymphoma. 2015 [Epub ahead of print]

140.

Martin PJ, Carpenter PA, Sanders JE, Flowers ME. Diagnosis and clinical management of chronic graft-versus-host disease. Int J Hematol. 2004;79:221–8.PubMedCrossRef

141.

Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988;72:546–54.PubMed

142.

Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood. 2000;96:3995–6.PubMed

143.

Arora M, Wagner JE, Davies SM, Blazar BR, Defor T, Enright H, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2001;7:265–73.CrossRef

144.

Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100:48–51.PubMedCrossRef

145.

Martin PJ, Storer BE, Rowley SD, Flowers ME, Lee SJ, Carpenter PA, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009;113:5074–82.PubMedCentralPubMed

146.

Gilman AL, Schultz KR, Goldman FD, Sale GE, Krailo MD, Chen Z, et al. Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children’s Oncology Group study. Biol Blood Marrow Transpl. 2012;18:84–91.CrossRef

147.

Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2011;17:1–17.

148.

Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365:2055–66.PubMedCentralPubMedCrossRef

149.

Okamoto M, Okano A, Akamatsu S, Ashihara E, Inaba T, Takenaka H, et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia. 2006;20:172–3.PubMedCrossRef

150.

Teshima T, Nagafuji K, Henzan H, Miyamura K, Takase K, Hidaka M, et al. Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. Int J Hematol. 2009;90:253–60.PubMedCrossRef

151.

Hidaka M, Iwasaki S, Matsui T, Kawakita T, Inoue Y, Sakai T, et al. Efficacy of bezafibrate for chronic GVHD of the liver after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 2010;45:912–8.CrossRef

152.

Nakaseko C, Ozawa S, Sakaida E, Sakai M, Kanda Y, Oshima K, et al. Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation. Int J Hematol. 2011;93:375–82.PubMedCrossRef

153.

Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation—an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2010;16:S106–14.CrossRef

154.

Nakasone H, Kanda J, Yano S, Atsuta Y, Ago H, Fukuda T, et al. A case-control study of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation. Transpl Int. 2013;26:631–9.PubMedCrossRef

155.

Okumura H, Ohtake S, Ontachi Y, Ozaki J, Shimadoi S, Waseda Y, et al. Living-donor lobar lung transplantation for broncho-bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: does bronchiolitis obliterans recur in transplanted lungs? Int J Hematol. 2007;86:369–73.

156.

Yamane M, Sano Y, Toyooka S, Okazaki M, Date H, Oto T. Living-donor lobar lung transplantation for pulmonary complications after hematopoietic stem cell transplantation. Transplantation. 2008;86:1767–70.PubMedCrossRef

157.

Date H. Update on living-donor lobar lung transplantation. Curr Opin Organ Transpl. 2011;16:453–7.CrossRef

158.

Ogawa Y, Dogru M, Uchino M, Tatematsu Y, Kamoi M, Yamamoto Y, et al. Topical tranilast for treatment of the early stage of mild dry eye associated with chronic GVHD. Bone Marrow Transpl. 2010;45:565–9.CrossRef

159.

Ogawa Y, Okamoto S, Mori T, Yamada M, Mashima Y, Watanabe R, et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transpl. 2003;31:579–83.CrossRef

160.

Yaguchi S, Ogawa Y, Kamoi M, Uchino M, Tatematsu Y, Ban Y, et al. Surgical management of lacrimal punctal cauterization in chronic GVHD-related dry eye with recurrent punctal plug extrusion. Bone Marrow Transpl. 2012;47:1465–9.CrossRef

161.

Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol. 2007;86:269–74.PubMedCrossRef

Titel: Prophylactic and therapeutic treatment of graft-versus-host disease in Japan
verfasst von: Makoto Murata
Publikationsdatum: 01.05.2015
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 5/2015
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-015-1784-2

Springer Medizin

Prophylactic and therapeutic treatment of graft-versus-host disease in Japan

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2015

Clinical significance of nontuberculous mycobacteria from respiratory specimens in stem cell transplantation recipients

Microcytic anemia in a pregnant woman: beyond iron deficiency

Recent topics in graft-versus-host disease: from the perspectives of pathogenesis and treatment

State-of-the-art acute and chronic GVHD treatment

Therapeutic benefits targeting B-cells in chronic graft-versus-host disease

Intestinal microbiota-related effects on graft-versus-host disease

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie